MDGL at Evercore yesterday | Biotech Message Board Posts


Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  48852 of 50472  at  12/2/2023 1:12:39 PM  by

sling5


 In response to msg 48847 by  lbl4321
view thread

Re: MDGL at Evercore yesterday

Why only 10%? There isnít another option. Also, it is an oral medication. No needle phobia or infusion centres. Once a day with a rather benign safety profile will encourage more patients to use it and more docs to prescribe it. Yes, I think the price will be closer to $70,000 and margins will be very high, likely over 90%. There will be a copay program but I think of that as expanding the market, not hurting margins
Now, being ultra conservative and using your $1.5B figure for US sales, what MC does Madrigal deserve when you also throw in ROW?

Iíll throw in a couple of quotes for everyone to chew on

We've been waiting for a long, long time for a therapy for these patients. Stephen Harrison, MD, lead investigator of the MAESTRO-NASH trial

EASL's vice secretary Aleksander Krag, MD, PhD, professor and head of hepatology at University of Southern Denmark and Odense University Hospital remarked, "This is so exciting. This phase 3 trial is a real game-changer in the field of fatty liver disease because it has nearly 1000 patients over 52 weeks of treatment."



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
48853 Re: MDGL at Evercore yesterday lbl4321 0 12/2/2023 1:44:38 PM




Financial Market Data provided by
.
Loading...